Welcome to our dedicated page for Intelgenx Technologies news (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on Intelgenx Technologies stock.
Intelgenx Technologies Corp (IGXT) specializes in advanced drug delivery solutions for pharmaceutical partners worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's proprietary technologies, strategic collaborations, and regulatory progress.
Track critical developments including formulation advancements, clinical trial milestones, manufacturing expansions, and partnership announcements. Our curated collection ensures timely access to verified press releases and objective reporting on IGXT's role in enhancing therapeutic outcomes through innovative delivery systems.
Discover updates spanning key operational areas: regulatory submissions for improved drug formulations, strategic licensing agreements with global partners, and manufacturing scale-up initiatives for optimized production. Bookmark this page for direct access to Intelgenx's official communications and third-party analyses of their pharmaceutical development progress.
IntelGenx Technologies Corp. (TSX:IGX, OTCQB:IGXT) will present a business update at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 9:30 a.m. ET, located at the Metro Toronto Convention Centre. The presentation will also be live-streamed and archived on the company's website under the Investors section. IntelGenx specializes in developing pharmaceutical films using advanced technologies such as VersaFilm®, DisinteQ™, VetaFilm™, and VevaDerm™. The company focuses on addressing unmet medical needs with its innovative product pipeline.
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) reported its financial results for 2021, highlighting significant corporate milestones, including graduation to the TSX and partnerships in the psychedelic space. Q4 revenue totaled $494,000, a decrease of 37% from Q4 2020, leading to a net comprehensive loss of $2.9 million. For the full year, revenue remained unchanged at $1.5 million, with a net comprehensive loss of $9.8 million. Recent developments include a $3 million term loan from atai and resumption of its Phase 2a clinical trial. The annual report will be filed today.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) will release its fourth quarter and full year 2021 financial results on March 24, 2022, after market close. The report will be followed by a conference call at 4:30 p.m. ET, hosted by CEO Dr. Horst G. Zerbe and CFO Andre Godin, providing insights into the company's performance and future outlook. The call will also be accessible via a live webcast on IntelGenx's website.
IntelGenx Corp. (TSX:IGX) announced the receipt of a third term loan of U.S.$3 million under its amended secured loan agreement with atai Life Sciences. This loan is guaranteed by IntelGenx. The company specializes in pharmaceutical films and offers advanced delivery systems like VersaFilm® and DisinteQ™. IntelGenx is dedicated to addressing unmet medical needs through innovative drug delivery technologies and comprehensive pharmaceutical services. The company is actively engaged in providing R&D and regulatory services to its partners.
IntelGenx Corp. (TSX:IGX) announced the resumption of patient dosing in its Phase 2a "BUENA" clinical trial for mild to moderate Alzheimer’s Disease after a COVID-related hiatus exceeding one year. This advancement highlights the ongoing repurposing of Montelukast VersaFilm®, with expectations for valuable insights into its safety and efficacy. Dr. Horst Zerbe, CEO, emphasized the significance of this milestone, while Dr. Ludwig Aigner noted the urgent need for effective AD treatments, positioning Montelukast VersaFilm® as a potential game-changer.
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has initiated arbitration against Tilray, Inc. due to an alleged breach of their 2018 license agreement regarding the co-development of cannabis-infused VersaFilm® products. IntelGenx asserts that Tilray's recent launch of competing medical cannabis oral strips represents a significant breach of contract. CEO Dr. Horst G. Zerbe emphasized their commitment to protecting commercial rights while prioritizing the availability of their innovative oral film products for cannabis consumers.
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) reported its third quarter 2021 financial results, revealing revenues of $593,000, up 16% from $510,000 in Q3 2020. The net comprehensive loss widened to $2.2 million, compared to $1.6 million last year. The company resumed patient screening in its Phase 2a clinical trial for Alzheimer’s, graduated to the TSX, and secured $6 million in future support from atai Life Sciences. However, operating costs increased to $2.2 million, leading to a loss per share of $0.01 as of September 30, 2021.
IntelGenx Technologies Corp. (TSX:IGX, OTCQB:IGXT) will release its third quarter 2021 financial results after market close on November 11, 2021. A conference call will be held at 4:30 p.m. ET featuring Dr. Horst G. Zerbe and Mr. Andre Godin to discuss the results and provide a business update. The call will also be live streamed on IntelGenx's website. The company focuses on developing pharmaceutical films and its technology aims to address unmet medical needs.
IntelGenx Corp. (TSX:IGX) has announced the resumption of patient screening for its Montelukast VersaFilm® Phase 2a (BUENA) clinical trial in Alzheimer’s Disease after receiving a No Objection Letter from Health Canada. The trial had been previously paused due to COVID-19 concerns affecting high-risk patients. CEO Dr. Horst Zerbe expressed excitement about evaluating Montelukast’s potential, highlighting financial support from a recent convertible notes offering as key to continuing the study.
IntelGenx Technologies Corp. (TSXV: IGX) has received final approval to graduate to the Toronto Stock Exchange (TSX) from the TSX Venture Exchange (TSXV). Trading of Common Shares, Convertible Debentures, and Warrants is set to commence on October 7, 2021. CEO Dr. Horst G. Zerbe emphasized that this transition marks a significant milestone and will enhance the company's profile in the investment community. The company’s securities will be delisted from the TSXV concurrently. IntelGenx specializes in pharmaceutical film technologies aimed at addressing unmet medical needs.
